ZA200205019B - 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives. - Google Patents
4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives. Download PDFInfo
- Publication number
- ZA200205019B ZA200205019B ZA200205019A ZA200205019A ZA200205019B ZA 200205019 B ZA200205019 B ZA 200205019B ZA 200205019 A ZA200205019 A ZA 200205019A ZA 200205019 A ZA200205019 A ZA 200205019A ZA 200205019 B ZA200205019 B ZA 200205019B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound according
- dihydro
- piperazin
- halogen
- indol
- Prior art date
Links
- -1 4-phenyl-1-piperazinyl Chemical group 0.000 title claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 84
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 208000019022 Mood disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 230000016571 aggressive behavior Effects 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 48
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 229960003638 dopamine Drugs 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 229940093499 ethyl acetate Drugs 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 229960004132 diethyl ether Drugs 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000000561 anti-psychotic effect Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 7
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000002152 alkylating effect Effects 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- MEALGJYIEAHDBR-UHFFFAOYSA-N 4-chloro-1-(2,3-dihydroindol-1-yl)butan-1-one Chemical compound C1=CC=C2N(C(=O)CCCCl)CCC2=C1 MEALGJYIEAHDBR-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229910000086 alane Inorganic materials 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000002178 crystalline material Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- JNARYGBSDJBKOG-UHFFFAOYSA-N 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)butan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCCC(=O)N3C4=CC=CC=C4CC3)CC2)=C1Cl JNARYGBSDJBKOG-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 3
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HKPJNPQCSYCCGY-UHFFFAOYSA-N 1-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound ClC1=CC=CC(N2CCN(CCCCN3C4=CC=CC=C4CCC3=O)CC2)=C1Cl HKPJNPQCSYCCGY-UHFFFAOYSA-N 0.000 description 2
- YDFFSYFADWCBNC-UHFFFAOYSA-N 1-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-2,3-dihydroindole Chemical compound ClC1=CC=CC(N2CCN(CCCCN3C4=CC=CC=C4CC3)CC2)=C1 YDFFSYFADWCBNC-UHFFFAOYSA-N 0.000 description 2
- FPEGGKCNMYDNMW-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetyl chloride Chemical class C1=CC=C2C(C(=O)C(=O)Cl)=CNC2=C1 FPEGGKCNMYDNMW-UHFFFAOYSA-N 0.000 description 2
- BXBUIQNPTIWLAY-UHFFFAOYSA-N 2-[(6-chloro-1h-indol-3-yl)sulfanyl]acetic acid Chemical compound ClC1=CC=C2C(SCC(=O)O)=CNC2=C1 BXBUIQNPTIWLAY-UHFFFAOYSA-N 0.000 description 2
- XWKXQKUUXBPOEI-UHFFFAOYSA-N 3-(4-chlorobutyl)-5-fluoro-1h-indole Chemical compound FC1=CC=C2NC=C(CCCCCl)C2=C1 XWKXQKUUXBPOEI-UHFFFAOYSA-N 0.000 description 2
- RRELOWFIYKQSSY-UHFFFAOYSA-N 3-[4-(3-chlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)propan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCC(=O)N3C4=CC=CC=C4CC3)CC2)=C1 RRELOWFIYKQSSY-UHFFFAOYSA-N 0.000 description 2
- SXEURMXMRSPUKK-UHFFFAOYSA-N 3-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-5-fluoro-1h-indole Chemical compound C12=CC(F)=CC=C2NC=C1CCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl SXEURMXMRSPUKK-UHFFFAOYSA-N 0.000 description 2
- LKCAABJNTGSTHY-UHFFFAOYSA-N 3-chloro-1-(2,3-dihydroindol-1-yl)propan-1-one Chemical compound C1=CC=C2N(C(=O)CCCl)CCC2=C1 LKCAABJNTGSTHY-UHFFFAOYSA-N 0.000 description 2
- ATQUGXCUUGMEAS-UHFFFAOYSA-N 4-[4-(2,4-difluorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)butan-1-one Chemical compound FC1=CC(F)=CC=C1N1CCN(CCCC(=O)N2C3=CC=CC=C3CC2)CC1 ATQUGXCUUGMEAS-UHFFFAOYSA-N 0.000 description 2
- KAGHFRSFZKKPBC-UHFFFAOYSA-N 4-[4-(2-chlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)butan-1-one Chemical compound ClC1=CC=CC=C1N1CCN(CCCC(=O)N2C3=CC=CC=C3CC2)CC1 KAGHFRSFZKKPBC-UHFFFAOYSA-N 0.000 description 2
- XQQIXGCGVXFGID-UHFFFAOYSA-N 5-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)pentan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCCCC(=O)N3C4=CC=CC=C4CC3)CC2)=C1Cl XQQIXGCGVXFGID-UHFFFAOYSA-N 0.000 description 2
- YTYIMDRWPTUAHP-UHFFFAOYSA-N 6-Chloroindole Chemical compound ClC1=CC=C2C=CNC2=C1 YTYIMDRWPTUAHP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 150000005623 oxindoles Chemical class 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 229950001675 spiperone Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- NIDRGFPZOWNAFU-UHFFFAOYSA-N 1-(1H-indol-2-yl)-1-piperazin-1-ylpropan-2-one Chemical class N1(CCNCC1)C(C(C)=O)C=1NC2=CC=CC=C2C1 NIDRGFPZOWNAFU-UHFFFAOYSA-N 0.000 description 1
- CICFHFOPXRHUSA-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)-4-[4-(2,3-dihydro-1h-inden-1-yl)butyl]piperazine Chemical compound ClC1=CC=CC(N2CCN(CCCCC3C4=CC=CC=C4CC3)CC2)=C1Cl CICFHFOPXRHUSA-UHFFFAOYSA-N 0.000 description 1
- CYQFNNSFAGXCEC-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)piperazine;hydrochloride Chemical compound [Cl-].ClC1=CC=CC(N2CC[NH2+]CC2)=C1Cl CYQFNNSFAGXCEC-UHFFFAOYSA-N 0.000 description 1
- ASNQRRSTZVDKIM-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-3-[4-(2-fluorophenyl)piperazin-1-yl]propan-1-one Chemical compound FC1=CC=CC=C1N1CCN(CCC(=O)N2C3=CC=CC=C3CC2)CC1 ASNQRRSTZVDKIM-UHFFFAOYSA-N 0.000 description 1
- GUTWDZXWTKMXPI-UHFFFAOYSA-N 1-(2-chlorophenyl)piperazin-4-ium;chloride Chemical compound Cl.ClC1=CC=CC=C1N1CCNCC1 GUTWDZXWTKMXPI-UHFFFAOYSA-N 0.000 description 1
- FVGUBMCWUSOXOS-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-4-[4-(2-fluorophenyl)piperazin-1-yl]butan-1-one Chemical compound FC1=CC=CC=C1N1CCN(CCCC(=O)N2CC3=CC=CC=C3CC2)CC1 FVGUBMCWUSOXOS-UHFFFAOYSA-N 0.000 description 1
- ODXDMSJYLPOYTN-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-5-[4-(2-fluorophenyl)piperazin-1-yl]pentan-1-one Chemical compound FC1=CC=CC=C1N1CCN(CCCCC(=O)N2CC3=CC=CC=C3CC2)CC1 ODXDMSJYLPOYTN-UHFFFAOYSA-N 0.000 description 1
- OSZCTRWSGNWWBL-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine;dihydrochloride Chemical compound Cl.Cl.ClC1=CC=CC(N2CCNCC2)=C1 OSZCTRWSGNWWBL-UHFFFAOYSA-N 0.000 description 1
- FWTGMJKTXCFLEL-UHFFFAOYSA-N 1-(4-bromobutyl)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(CCCCBr)C(=O)CCC2=C1 FWTGMJKTXCFLEL-UHFFFAOYSA-N 0.000 description 1
- XWBSYXSSJIMQFP-UHFFFAOYSA-N 1-[3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]-2,3-dihydroindole Chemical compound ClC1=CC=CC(N2CCN(CCCN3C4=CC=CC=C4CC3)CC2)=C1Cl XWBSYXSSJIMQFP-UHFFFAOYSA-N 0.000 description 1
- CRNKXSKVAPWEMK-UHFFFAOYSA-N 1-[3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]-2,3-dihydroindole hydrochloride Chemical compound Cl.Clc1cccc(N2CCN(CCCN3CCc4ccccc34)CC2)c1Cl CRNKXSKVAPWEMK-UHFFFAOYSA-N 0.000 description 1
- NXVXNFMCMJYLNQ-UHFFFAOYSA-N 1-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-2,3-dihydroindole Chemical compound ClC1=CC=CC(N2CCN(CCCCN3C4=CC=CC=C4CC3)CC2)=C1Cl NXVXNFMCMJYLNQ-UHFFFAOYSA-N 0.000 description 1
- ONVMJZRBJDUEIT-UHFFFAOYSA-N 1-[4-[4-(2-chlorophenyl)piperazin-1-yl]butyl]-2,3-dihydroindole Chemical compound ClC1=CC=CC=C1N1CCN(CCCCN2C3=CC=CC=C3CC2)CC1 ONVMJZRBJDUEIT-UHFFFAOYSA-N 0.000 description 1
- GHZFHCJWGMRSDW-UHFFFAOYSA-N 1-[5-[4-(2,3-dichlorophenyl)piperazin-1-yl]pentyl]-2,3-dihydroindole Chemical compound ClC1=CC=CC(N2CCN(CCCCCN3C4=CC=CC=C4CC3)CC2)=C1Cl GHZFHCJWGMRSDW-UHFFFAOYSA-N 0.000 description 1
- YKSVXVKIYYQWBB-UHFFFAOYSA-N 1-butylpiperazine Chemical compound CCCCN1CCNCC1 YKSVXVKIYYQWBB-UHFFFAOYSA-N 0.000 description 1
- VBRZCUSAPANGLA-UHFFFAOYSA-N 2-(6-chloro-1h-indol-3-yl)ethanol Chemical compound ClC1=CC=C2C(CCO)=CNC2=C1 VBRZCUSAPANGLA-UHFFFAOYSA-N 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical class C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 1
- YUBXEUBNYOBJMQ-UHFFFAOYSA-N 3-(3-bromopropyl)-1h-indole Chemical compound C1=CC=C2C(CCCBr)=CNC2=C1 YUBXEUBNYOBJMQ-UHFFFAOYSA-N 0.000 description 1
- PUAUYHRDZBOSNM-UHFFFAOYSA-N 3-(3-chloropropyl)-5-fluoro-1h-indole Chemical compound FC1=CC=C2NC=C(CCCCl)C2=C1 PUAUYHRDZBOSNM-UHFFFAOYSA-N 0.000 description 1
- ZMEDIPHPVZBLSY-UHFFFAOYSA-N 3-(4-bromobutyl)-1h-indole Chemical compound C1=CC=C2C(CCCCBr)=CNC2=C1 ZMEDIPHPVZBLSY-UHFFFAOYSA-N 0.000 description 1
- DNTBKMJDCRVWKV-UHFFFAOYSA-N 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)propan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCC(=O)N3CC4=CC=CC=C4CC3)CC2)=C1Cl DNTBKMJDCRVWKV-UHFFFAOYSA-N 0.000 description 1
- AZNZRRREZBGIEP-UHFFFAOYSA-N 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(5-fluoro-2,3-dihydroindol-1-yl)propan-1-one Chemical compound C1CC2=CC(F)=CC=C2N1C(=O)CCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl AZNZRRREZBGIEP-UHFFFAOYSA-N 0.000 description 1
- LVMASTNYYWAFPR-UHFFFAOYSA-N 3-[4-(2,4-difluorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)propan-1-one Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC(=O)N2C3=CC=CC=C3CC2)CC1 LVMASTNYYWAFPR-UHFFFAOYSA-N 0.000 description 1
- OHBWPESHUPGWOZ-UHFFFAOYSA-N 3-[4-(2-chlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)propan-1-one Chemical compound ClC1=CC=CC=C1N1CCN(CCC(=O)N2C3=CC=CC=C3CC2)CC1 OHBWPESHUPGWOZ-UHFFFAOYSA-N 0.000 description 1
- LAPHWPCOOJUJRD-UHFFFAOYSA-N 3-[4-(2-chlorophenyl)piperazin-1-yl]-1-(5-fluoro-2,3-dihydroindol-1-yl)propan-1-one Chemical compound C1CC2=CC(F)=CC=C2N1C(=O)CCN(CC1)CCN1C1=CC=CC=C1Cl LAPHWPCOOJUJRD-UHFFFAOYSA-N 0.000 description 1
- AZQWXUKTUPDWFC-UHFFFAOYSA-N 3-[4-(3,4-dichlorophenyl)piperazin-1-yl]-1-(5-fluoro-2,3-dihydroindol-1-yl)propan-1-one Chemical compound C1CC2=CC(F)=CC=C2N1C(=O)CCN(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 AZQWXUKTUPDWFC-UHFFFAOYSA-N 0.000 description 1
- PTSGYRFZWZIQQO-UHFFFAOYSA-N 3-[4-(3-chlorophenyl)piperazin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)propan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCC(=O)N3CC4=CC=CC=C4CC3)CC2)=C1 PTSGYRFZWZIQQO-UHFFFAOYSA-N 0.000 description 1
- UQNNOLFCSXHDPB-UHFFFAOYSA-N 3-[4-(3-chlorophenyl)piperazin-1-yl]-1-(5-fluoro-2,3-dihydroindol-1-yl)propan-1-one Chemical compound C1CC2=CC(F)=CC=C2N1C(=O)CCN(CC1)CCN1C1=CC=CC(Cl)=C1 UQNNOLFCSXHDPB-UHFFFAOYSA-N 0.000 description 1
- HSAWXMFIKDUJQH-UHFFFAOYSA-N 3-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-1H-indole hydrochloride Chemical compound Cl.Clc1cccc(N2CCN(CCCCc3c[nH]c4ccccc34)CC2)c1Cl HSAWXMFIKDUJQH-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- KXNZMTSWQDRFMG-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-1-yl)butanoic acid Chemical compound C1=CC=C2C(CCCC(=O)O)CCC2=C1 KXNZMTSWQDRFMG-UHFFFAOYSA-N 0.000 description 1
- LIKNWMXZRDCXFT-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-1-yl)butyl methanesulfonate Chemical compound C1=CC=C2C(CCCCOS(=O)(=O)C)CCC2=C1 LIKNWMXZRDCXFT-UHFFFAOYSA-N 0.000 description 1
- OYUPMBIJOWFVHE-UHFFFAOYSA-N 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)butan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCCC(=O)N3CC4=CC=CC=C4CC3)CC2)=C1Cl OYUPMBIJOWFVHE-UHFFFAOYSA-N 0.000 description 1
- IFXXMCDSRYUWPA-UHFFFAOYSA-N 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-(5-fluoro-2,3-dihydroindol-1-yl)butan-1-one Chemical compound C1CC2=CC(F)=CC=C2N1C(=O)CCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl IFXXMCDSRYUWPA-UHFFFAOYSA-N 0.000 description 1
- WXUTUWPWGWAHFF-UHFFFAOYSA-N 4-[4-(2-chlorophenyl)piperazin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)butan-1-one Chemical compound ClC1=CC=CC=C1N1CCN(CCCC(=O)N2CC3=CC=CC=C3CC2)CC1 WXUTUWPWGWAHFF-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- LCXNTJHJBSFODM-UHFFFAOYSA-N 5-[4-(2,4-difluorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)pentan-1-one Chemical compound FC1=CC(F)=CC=C1N1CCN(CCCCC(=O)N2C3=CC=CC=C3CC2)CC1 LCXNTJHJBSFODM-UHFFFAOYSA-N 0.000 description 1
- ZSIQCZXPNKRMSY-UHFFFAOYSA-N 5-[4-(2-chlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)pentan-1-one Chemical compound ClC1=CC=CC=C1N1CCN(CCCCC(=O)N2C3=CC=CC=C3CC2)CC1 ZSIQCZXPNKRMSY-UHFFFAOYSA-N 0.000 description 1
- ZQMMVHNSBOQNKY-UHFFFAOYSA-N 5-[4-(3-chlorophenyl)piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)pentan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCCCC(=O)N3C4=CC=CC=C4CC3)CC2)=C1 ZQMMVHNSBOQNKY-UHFFFAOYSA-N 0.000 description 1
- UBQPJUSYJZRPLJ-UHFFFAOYSA-N 5-[4-(3-chlorophenyl)piperazin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)pentan-1-one Chemical compound ClC1=CC=CC(N2CCN(CCCCC(=O)N3CC4=CC=CC=C4CC3)CC2)=C1 UBQPJUSYJZRPLJ-UHFFFAOYSA-N 0.000 description 1
- OKRUMSWHDWKGHA-UHFFFAOYSA-N 5-bromopentanoyl chloride Chemical compound ClC(=O)CCCCBr OKRUMSWHDWKGHA-UHFFFAOYSA-N 0.000 description 1
- DCBJCKDOZLTTDW-UHFFFAOYSA-N 5-chloropentan-1-ol Chemical compound OCCCCCCl DCBJCKDOZLTTDW-UHFFFAOYSA-N 0.000 description 1
- ZNLHWEDEIKEQDK-UHFFFAOYSA-N 5-chloropentanal Chemical compound ClCCCCC=O ZNLHWEDEIKEQDK-UHFFFAOYSA-N 0.000 description 1
- NXQRMQIYCWFDGP-UHFFFAOYSA-N 5-fluoro-2,3-dihydro-1h-indole Chemical compound FC1=CC=C2NCCC2=C1 NXQRMQIYCWFDGP-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- QVLKOZPWKQBRLU-UHFFFAOYSA-N 6-chloro-3-(3-iodopropyl)-1H-indole (4-fluorophenyl)hydrazine hydrochloride Chemical compound ClC1=CC=C2C(=CNC2=C1)CCCI.Cl.FC1=CC=C(C=C1)NN QVLKOZPWKQBRLU-UHFFFAOYSA-N 0.000 description 1
- LHYAKHISBDQPNK-UHFFFAOYSA-N 6-chloro-3-(3-iodopropyl)-1h-indole Chemical compound ClC1=CC=C2C(CCCI)=CNC2=C1 LHYAKHISBDQPNK-UHFFFAOYSA-N 0.000 description 1
- UTPPGNQFLRXTJD-UHFFFAOYSA-N 6-chloro-3-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethylsulfanyl]-1h-indole Chemical compound C=1NC2=CC(Cl)=CC=C2C=1SCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl UTPPGNQFLRXTJD-UHFFFAOYSA-N 0.000 description 1
- RANBJTZWNOAHKL-UHFFFAOYSA-N 6-chloro-3-[3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]-1h-indole Chemical compound C=1NC2=CC(Cl)=CC=C2C=1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl RANBJTZWNOAHKL-UHFFFAOYSA-N 0.000 description 1
- JNTPTNNCGDAGEJ-UHFFFAOYSA-N 6-chlorohexan-1-ol Chemical compound OCCCCCCCl JNTPTNNCGDAGEJ-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QEWCAJDEIBCAIQ-UHFFFAOYSA-N Cl.ClC1=CC=CC(N2CCN(CCCC=3C4=CC=CC=C4NC=3)CC2)=C1Cl Chemical compound Cl.ClC1=CC=CC(N2CCN(CCCC=3C4=CC=CC=C4NC=3)CC2)=C1Cl QEWCAJDEIBCAIQ-UHFFFAOYSA-N 0.000 description 1
- CNWBKIQCLBFKLH-UHFFFAOYSA-N ClCCCC1=CNC2=CC=C(C=C12)F.BrCCCCC1=CNC2=CC=CC=C12.BrCCCC1=CNC2=CC=CC=C12 Chemical compound ClCCCC1=CNC2=CC=C(C=C12)F.BrCCCCC1=CNC2=CC=CC=C12.BrCCCC1=CNC2=CC=CC=C12 CNWBKIQCLBFKLH-UHFFFAOYSA-N 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 102000004084 Dopamine D5 Receptors Human genes 0.000 description 1
- 108090000541 Dopamine D5 Receptors Proteins 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000000706 effect on dopamine Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940077844 iodine / potassium iodide Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901887 | 1999-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205019B true ZA200205019B (en) | 2003-09-22 |
Family
ID=8108820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205019A ZA200205019B (en) | 1999-12-30 | 2002-06-21 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives. |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7074796B2 (xx) |
| EP (2) | EP1464641B1 (xx) |
| JP (1) | JP2003519225A (xx) |
| KR (2) | KR100729536B1 (xx) |
| CN (2) | CN1803784A (xx) |
| AR (1) | AR029461A1 (xx) |
| AT (2) | ATE395333T1 (xx) |
| AU (2) | AU783786B2 (xx) |
| BG (1) | BG106960A (xx) |
| BR (1) | BR0016953A (xx) |
| CA (1) | CA2395869C (xx) |
| CZ (1) | CZ20022603A3 (xx) |
| DE (2) | DE60011817T2 (xx) |
| DK (2) | DK1246817T3 (xx) |
| EA (2) | EA005013B1 (xx) |
| ES (2) | ES2223628T3 (xx) |
| HK (1) | HK1055960A1 (xx) |
| HR (1) | HRP20020567A2 (xx) |
| HU (1) | HUP0203839A3 (xx) |
| IL (3) | IL150366A0 (xx) |
| IS (1) | IS6432A (xx) |
| MX (1) | MXPA02006590A (xx) |
| NO (2) | NO323401B1 (xx) |
| NZ (2) | NZ519740A (xx) |
| PL (1) | PL355502A1 (xx) |
| PT (2) | PT1464641E (xx) |
| SG (1) | SG152900A1 (xx) |
| SK (1) | SK11072002A3 (xx) |
| TR (2) | TR200201690T2 (xx) |
| UA (1) | UA73756C2 (xx) |
| WO (1) | WO2001049679A1 (xx) |
| ZA (1) | ZA200205019B (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1272187B1 (de) * | 2000-03-27 | 2008-07-30 | Abbott GmbH & Co. KG | Dopamin-d3-rezeptor-liganden zur behandlung von sucht |
| GB0117577D0 (en) * | 2001-02-16 | 2001-09-12 | Aventis Pharm Prod Inc | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands |
| FR2831166B1 (fr) | 2001-10-18 | 2004-02-27 | Sanofi Synthelabo | Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant |
| US7550459B2 (en) * | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| EP1461318B9 (en) | 2001-12-28 | 2005-12-28 | Acadia Pharmaceuticals Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| WO2005061455A1 (en) | 2003-12-23 | 2005-07-07 | H. Lundbeck A/S | 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri |
| DE102004027358A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
| FR2878524B1 (fr) * | 2004-12-01 | 2007-01-19 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
| US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
| AR054393A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| CN104337812B (zh) | 2013-07-29 | 2018-09-14 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其使用方法和用途 |
| CN104725359B (zh) | 2013-12-20 | 2017-05-03 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
| WO2016192657A1 (en) | 2015-06-03 | 2016-12-08 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB944443A (xx) * | 1959-09-25 | 1900-01-01 | ||
| US3468882A (en) | 1966-10-07 | 1969-09-23 | Sterling Drug Inc | Phenylhydrazone derivatives as intermediates for preparing indoles |
| DE2138865A1 (de) * | 1970-08-15 | 1973-02-22 | Sumitomo Chemical Co | 3-indolylpiperazine, verfahren zu ihrer herstellung und arzneimittel |
| FR2635104B1 (fr) * | 1988-08-03 | 1992-04-30 | Synthelabo | Derives d'indolone, leur preparation et leur application en therapeutique |
| US4950664A (en) * | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
| DE4101686A1 (de) | 1991-01-22 | 1992-07-23 | Merck Patent Gmbh | Indolderivate |
| US5556857A (en) * | 1991-05-08 | 1996-09-17 | Otsuka Pharmaceutical Co., Ltd. | Disturbance-of-consciousness improving agent |
| IT1255178B (it) * | 1992-06-26 | 1995-10-20 | Pierrel Spa | N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica |
| WO1994024105A1 (en) * | 1993-04-15 | 1994-10-27 | Merck Sharp & Dohme Limited | Indole derivatives as dopamine d4 antagonists |
| DK1153603T3 (da) * | 1993-06-28 | 2006-12-18 | Wyeth Corp | Nye behandlingsmetoder ved anvendelse af phenethylaminderivater |
| DE59509727D1 (de) * | 1994-12-07 | 2001-11-22 | Byk Gulden Lomberg Chem Fab | Uracilderivate |
| WO1998008816A1 (fr) * | 1996-08-26 | 1998-03-05 | Meiji Seika Kaisha, Ltd. | Derives d'indoxyle et psychotropes |
| TR200000414T2 (tr) * | 1997-08-15 | 2000-08-21 | Pfizer Products Inc. | 2-(4-Aril ya da heteroaril-piperazin-1-ilmetil)-1H-indol türevleri. |
| US6355644B1 (en) * | 1999-06-14 | 2002-03-12 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
| US6376514B1 (en) * | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| TW580446B (en) * | 2003-05-15 | 2004-03-21 | Benq Corp | Color electrode array printer |
-
2000
- 2000-12-22 CA CA002395869A patent/CA2395869C/en not_active Expired - Fee Related
- 2000-12-22 KR KR1020027008576A patent/KR100729536B1/ko not_active IP Right Cessation
- 2000-12-22 JP JP2001550219A patent/JP2003519225A/ja active Pending
- 2000-12-22 AT AT04007739T patent/ATE395333T1/de not_active IP Right Cessation
- 2000-12-22 EP EP04007739A patent/EP1464641B1/en not_active Expired - Lifetime
- 2000-12-22 TR TR2002/01690T patent/TR200201690T2/xx unknown
- 2000-12-22 BR BR0016953-6A patent/BR0016953A/pt not_active Application Discontinuation
- 2000-12-22 CZ CZ20022603A patent/CZ20022603A3/cs unknown
- 2000-12-22 ES ES00984931T patent/ES2223628T3/es not_active Expired - Lifetime
- 2000-12-22 MX MXPA02006590A patent/MXPA02006590A/es active IP Right Grant
- 2000-12-22 CN CNA2005101310970A patent/CN1803784A/zh active Pending
- 2000-12-22 NZ NZ519740A patent/NZ519740A/en unknown
- 2000-12-22 DE DE60011817T patent/DE60011817T2/de not_active Expired - Fee Related
- 2000-12-22 CN CNB00819145XA patent/CN1244577C/zh not_active Expired - Fee Related
- 2000-12-22 EA EA200200729A patent/EA005013B1/ru not_active IP Right Cessation
- 2000-12-22 KR KR1020077000879A patent/KR100792186B1/ko not_active IP Right Cessation
- 2000-12-22 DK DK00984931T patent/DK1246817T3/da active
- 2000-12-22 SK SK1107-2002A patent/SK11072002A3/sk unknown
- 2000-12-22 PL PL00355502A patent/PL355502A1/xx not_active IP Right Cessation
- 2000-12-22 WO PCT/DK2000/000728 patent/WO2001049679A1/en active Application Filing
- 2000-12-22 EA EA200400641A patent/EA008627B1/ru not_active IP Right Cessation
- 2000-12-22 TR TR2004/02408T patent/TR200402408T4/xx unknown
- 2000-12-22 SG SG200405552-1A patent/SG152900A1/en unknown
- 2000-12-22 AU AU21527/01A patent/AU783786B2/en not_active Ceased
- 2000-12-22 NZ NZ530137A patent/NZ530137A/en unknown
- 2000-12-22 ES ES04007739T patent/ES2302992T3/es not_active Expired - Lifetime
- 2000-12-22 DK DK04007739T patent/DK1464641T3/da active
- 2000-12-22 UA UA2002065264A patent/UA73756C2/uk unknown
- 2000-12-22 DE DE60038911T patent/DE60038911D1/de not_active Expired - Fee Related
- 2000-12-22 HU HU0203839A patent/HUP0203839A3/hu unknown
- 2000-12-22 AT AT00984931T patent/ATE269857T1/de not_active IP Right Cessation
- 2000-12-22 IL IL15036600A patent/IL150366A0/xx active IP Right Grant
- 2000-12-22 PT PT04007739T patent/PT1464641E/pt unknown
- 2000-12-22 PT PT00984931T patent/PT1246817E/pt unknown
- 2000-12-22 EP EP00984931A patent/EP1246817B1/en not_active Expired - Lifetime
- 2000-12-28 AR ARP000106991A patent/AR029461A1/es not_active Application Discontinuation
-
2002
- 2002-06-19 IS IS6432A patent/IS6432A/is unknown
- 2002-06-21 ZA ZA200205019A patent/ZA200205019B/en unknown
- 2002-06-23 IL IL150366A patent/IL150366A/en not_active IP Right Cessation
- 2002-06-27 US US10/186,339 patent/US7074796B2/en not_active Expired - Fee Related
- 2002-06-28 NO NO20023151A patent/NO323401B1/no unknown
- 2002-07-03 HR HR20020567A patent/HRP20020567A2/hr not_active Application Discontinuation
- 2002-07-26 BG BG106960A patent/BG106960A/bg unknown
-
2003
- 2003-11-13 HK HK03108252A patent/HK1055960A1/xx unknown
-
2006
- 2006-03-08 AU AU2006201000A patent/AU2006201000A1/en not_active Abandoned
- 2006-03-15 US US11/377,772 patent/US7223765B2/en not_active Expired - Fee Related
- 2006-12-14 NO NO20065681A patent/NO20065681L/no not_active Application Discontinuation
-
2007
- 2007-10-25 IL IL186954A patent/IL186954A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7223765B2 (en) | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | |
| US7601837B2 (en) | Quinoline derivatives and their use as 5-HT6 ligands | |
| ZA200204970B (en) | Phenylpiperazinyl derivatives. | |
| CA2411412C (en) | Indole derivatives useful for the treatment of cns disorders | |
| AU2001273881A1 (en) | Indole derivatives useful for the treatment of CNS disorders | |
| ZA200209886B (en) | Indole derivatives useful for the treatment of CNS disorders. | |
| NZ540801A (en) | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | |
| EP1468996B1 (en) | Indole derivatives for the treatment of CNS disorders | |
| IL153234A (en) | Indole derivatives and pharmaceutical compositions containing them for the treatment of cns disorders | |
| MXPA02012149A (en) | Indole derivatives useful for the treatment of cns disorders |